Brief: Iridex Announces First Patient Enrolled In An Independent Landmark Investigator
24/06/2025 12:08
June 24 (Reuters) - IRIDEX Corp IRIX.O: IRIDEX ANNOUNCES FIRST PATIENT ENROLLED IN AN INDEPENDENT LANDMARK INVESTIGATOR-LED UK STUDY EVALUATING MICROPULSE® TECHNOLOGY AS AN ADJUNCT TO ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA Source text: ID:nGNX4frs6v Further company coverage: IRIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IRIDEX
See all newsIridex Q1 revenue falls 1%, loss narrows
Iridex Q4 revenue rises on higher retina system sales
Laser eye device maker Iridex's Q3 net loss narrows
Brief: Iridex Corporation Receives Formal Notification Of Nasdaq Listing Compliance
Brief: Iridex Announces First Patient Enrolled In An Independent Landmark Investigator